- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03551392
Pilot Intervention With Near Infrared Stimulation
Pilot Intervention With Near Infrared Stimulation: Revitalizing Cognition in Older Adults and Those With Parkinson Disease
Study Overview
Status
Conditions
Detailed Description
This is a pilot study of the efficacy of NIR stimulation for enhancing cognition and mood in nondemented older adults including individuals with Parkinson disease. Prior research suggests that NIR exposure may be neuroprotective and increases energy available to neurons. The current study will test whether age-related cognitive and mood changes in older adults and those with Parkinson disease will be affected by near infrared (NIR) stimulation.
The study team will randomize older adults and those with Parkinson disease into treatment groups and evaluate neuroimaging and cognitive outcome measures, before and after an 12-week intervention involving transcranial and intranasal NIR. The protocol will involve both " lab" and " home-based" NIR stimulation. The overall hypothesis, drawn from previous literature, is that exposure to NIR stimulation will have positive effects on brain health and will result in better cognitive and mood performance.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Dawn Bowers, Ph.D.
- Phone Number: 352-273-5270
- Email: dawnbowers@Phhp.ufl.edu
Study Contact Backup
- Name: Adam Woods, Ph.D.
- Phone Number: 352-294-5842
- Email: ajwoods@phhp.ufl.edu
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85721
- Recruiting
- University of Arizona
-
-
Florida
-
Gainesville, Florida, United States, 32611
- Recruiting
- University of Florida
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- No evidence of dementia or Mild Cognitive Impairment based on cognitive screening (i.e., Montreal Cognitive Assessment (MoCA) scores within normal limits for age , education, and sex using the NACC Uniform Data Set (UDS) norms or Dementia Rating Scale (DRS-2) scores <5thile), and age-appropriate delayed Story recall (i.e., WMS-III Logical Memory) and confrontation naming (Boston Naming Test)
- Able to provide informed consent and perform cognitive and mood measures on a computer
- At least 8th grade education and/or ability to read at 8th grade level
- Willingness to be randomized to Sham or Real intervention
- Can devote 12 weeks to the intervention, and additional time for pre and post testing
- On stable doses of major medications; Since some older adults with subjective memory complaints may be prescribed acetylcholinererase inhibitors or related medications by their primary care physicians (i.e., donepezil, rivastigmine, galantaominhe, memantime, or other potential memory-enhancing agent(s), we will not exclude them as long as they have been on stable medications for at least two months and plan to continue this medication during study participation.
- Normal functional behavior in terms of daily activities
Exclusion Criteria:
- Previous major strokes or other known significant brain abnormalities or diseases affecting cognition (i.e., multiple sclerosis, seizure disorder, brain surgery, moderate TBI, etc.). No history of brain surgery. Exceptions are a diagnosis of Parkinson's disease for the PD subgroup.
- Unstable and uncontrolled medical conditions (metabolic encephalopathy, HIV, moderate to severe kidney or liver disease)
- Current or past history of major psychiatric disturbance including schizophrenia, or active psychosis, bipolar disorder, current major depressive episode, current alcohol or substance abuse or history thereof within the past six months. The study team is not excluding individuals who are taking antidepressants or anti-anxiety medications, however, use of antidepressants and anxiolytics will be recorded and data will be analyzed in post-hoc analyses
- Use of antipsychotics, sedatives, or other medications with significant anticholinergic properties (due to potential influence on memory)
- Use of photo-sensitive medications such as steroids or retin-A within 15 days of the study intervention
- Diagnosis of active cancer
- Significant motor or visual disturbance that would prevent one from using a computer or detecting colors
- Previous participation in a cognitive training study within the last 3 months or current involvement in another study involving cognitive training or intervention at the time of participation
- Inability to undergo brain imaging due to claustrophobia or implants such as pacemakers, heart valves, brain aneurysm clips, orthodontics, non-removable body jewelry, or shrapnel containing ferromagnetic metal
Additional criteria for participants in Parkinson group
- Participants must have a diagnosis of idiopathic Parkinson's disease by a movement disorders specialist based on UK Brain Bank criteria
- No previous history of brain surgery (DBS, pallidotomy, thalamotomy, or fetal cell implants).
- May have difficulties with activities of daily living, but this is due to physical symptoms of Parkinson disease and not because of cognitive problems
- Hoehn-Yahr staging between .5 and 3.5
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: NIR -Older Adult
Older adult participants receive the Medx Console System and the Vielight 810 intranasal stand alone unit.
These interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
|
This intervention delivers near infrared (NIR) light using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours.
A total of 16 sessions take place in the lab over 12 weeks.
Other Names:
Daily at home intranasal NIR stimulation sessions, 25 minutes in duration, 4 days each week.
|
Sham Comparator: No Dose NIR-Older Adult
Older adult participants receive the sham Medx Console System and the sham Vielight 810 intranasal stand alone unit, since the devices deliver no near infrared light.
These sham interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
|
This intervention uses sham application of near infrared light (NIR) using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours.
A total of 16 sessions take place in the lab over 12 weeks.
Daily at home intranasal "sham" NIR stimulation sessions, 25 minutes in duration, 4 days each week.
|
Active Comparator: NIR -Parkinson
Participants with Parkinson disease receive the Medx Console System and the Vielight 810 intranasal stand alone unit.
These interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
|
This intervention delivers near infrared (NIR) light using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours.
A total of 16 sessions take place in the lab over 12 weeks.
Other Names:
Daily at home intranasal NIR stimulation sessions, 25 minutes in duration, 4 days each week.
|
Sham Comparator: No Dose NIR-Parkinson
Participants with Parkinson disease receive the sham Medx Console System and the sham Vielight 810 intranasal stand alone unit, since the devices deliver no near infrared light.
These sham interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
|
This intervention uses sham application of near infrared light (NIR) using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours.
A total of 16 sessions take place in the lab over 12 weeks.
Daily at home intranasal "sham" NIR stimulation sessions, 25 minutes in duration, 4 days each week.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ARENA, learning and memory change from baseline to post-testing
Time Frame: Baseline to one-week post intervention (approx Week 14)
|
Spatial navigation and memory task yields a score consisting of percent time spent in the target quadrant during the probe trial.
|
Baseline to one-week post intervention (approx Week 14)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
NIH Examiner Executive Composite Score change from baseline to post-testing
Time Frame: Change in baseline to one week post intervention (approx Week 14)
|
Computer based battery of executive function tests which yields a total or 'composite' score to represent global executive functioning.
Executive composite scores can range from -3.0 to 3.0 with higher scores corresponding to better executive functioning, and negative scores indicating impairment.
A change score will be calculated by subtracting the baseline scores from the post-test scores.
|
Change in baseline to one week post intervention (approx Week 14)
|
NIH Toolbox Emotion Negative Affect Scale change from baseline to post-testing
Time Frame: Baseline to one-week post-intervention (approx Week 14)
|
The Negative Affect Scale from the NIH Toolbox Emotion module results in T-scores (mean=50, SD=10) for categories such as anger, sadness, and apathy.
Scores below 40 indicate low levels of negative affect.
Change scores will be calculated by subtracting the baseline scores from the post-test scores.
|
Baseline to one-week post-intervention (approx Week 14)
|
NIH Examiner, Verbal Fluency Domain Score change from baseline
Time Frame: Change in baseline to one-week post intervention (approx Week 14)
|
The Verbal Fluency domain from the NIH Examiner involves speeded production of letter and semantic cued words.
Verbal fluency composite score can range from -3.0 to 3.0, with higher scores corresponding to better fluency performance and negative scores indicating impairment.
A change score will be calculated by subtracting the baseline scores from the post test scores.
|
Change in baseline to one-week post intervention (approx Week 14)
|
NIH Examiner, Working Memory Domain score change from baseline
Time Frame: Change in baseline to one-week post intervention (approx Week 14)
|
Computer based battery of working memory tasks that yields a composite score based on Dot Counting total score and d-prime measures from the N-back task.
Composite score ranges from -3.0 to 3.0, with higher scores corresponding to better working memory performance.
A change score will be calculated by subtracting the baseline scores from the post test scores.
|
Change in baseline to one-week post intervention (approx Week 14)
|
NIH Examiner, Cognitive Control Domain score change from baseline to post-testing
Time Frame: Change in baseline to one-week post intervention (approx Week 14)
|
The Cognitive Control domain from the NIH Examiner yields a composite score based on individual scores from the Flanker task, the Continuous Performance task, and the Set-Shifting task.
Composite score ranges from -3.0 to 3.0, with higher scores corresponding to better cognitive control performance.
A change score will be calculated by subtracting the baseline scores from the post test scores.
|
Change in baseline to one-week post intervention (approx Week 14)
|
NIH Toolbox Emotion-Psychological Well Being Scale change from baseline
Time Frame: Change in baseline to one-week post intervention (approx Week 14)
|
The Psychological Well-being Scale from the NIH Toolbox Emotion module results in T-scores (mean=50, SD=10) for categories such general life satisfaction, meaning and purpose, and positive affect.
Scores below 40 indicate low levels of positive affect.
Change scores will be calculated by subtracting the baseline scores from the post-test scores.
|
Change in baseline to one-week post intervention (approx Week 14)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Adam Woods, Ph.D., University of Florida
- Principal Investigator: Gene Alexander, Ph.D., University of Arizona
- Principal Investigator: Dawn Bowers, Ph.D., University of Florida
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB201801152
- OCR18061 (Other Identifier: University of Florida)
- PRO00020250 (Other Identifier: UFIRST)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Medx Console System
-
Boston Children's HospitalUnited States Department of Defense; National Football LeagueCompleted
-
University of FloridaParkinson's Foundation; FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMERRecruiting
-
Spaulding Rehabilitation HospitalCompleted
-
Yan'an Affiliated Hospital of Kunming Medical UniversityShanghai Zhongshan Hospital; Kunming Chenggong District People's HospitalNot yet recruitingMyocardial Ischemia | Cardiovascular Diseases | Coronary Artery Disease | Coronary Disease | Arteriosclerosis
-
Miracor Medical SACompleted
-
Centre Hospitalier Universitaire de Saint EtienneFondation de FranceTerminatedOsteogenesis ImperfectaFrance
-
SynCardia Systems. LLCEnrolling by invitation
-
Nottingham Trent UniversityUniversity of Hull; Nottingham University Hospitals NHS Trust; Bournemouth University and other collaboratorsTerminatedLower Limb AmputationUnited Kingdom
-
NinePoint MedicalCompletedUndergoing Esophagogastroduodenoscopy (EGD)United States
-
Fujita Health UniversityUnknownCoronary Artery DiseaseJapan